Phase II trial as new chemotherapy regimen for bevacizumab (Bev) in combination with XELOX in unresectable colorectal cancer.
收藏NIAID Data Ecosystem2026-03-07 收录
官方服务：
资源简介：
Interventions: XELOX+BV 5-days on/ 2-days off Schedule Primary outcome(s): Progression free survival. Study Design: Single arm Non-randomized
创建时间：
2013-04-15
